TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31043758

Group type: EXPERIMENTAL
Intervention: Maternal blood pressure‐raising alleles
Number of subjects: 230069

Group type: EXPERIMENTAL
Intervention: Direct fetal genetic effects of maternal blood pressure‐raising alleles
Number of subjects: 230069

Group type: EXPERIMENTAL
Intervention: Maternal birth weight‐lowering genotypes
Number of subjects: 230069
Study: 27655380

Group type: EXPERIMENTAL
Intervention: Transoral fundoplication (TF)
Number of subjects: 63
Study: 25090135

Group type: EXPERIMENTAL
Intervention: 0.014‐inch superelastic nickel‐titanium (NiTi)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.014‐inch thermoelastic NiTi
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.014‐inch conventional NiTi
Number of subjects: 74
Study: 24330986

Group type: EXPERIMENTAL
Intervention: ER XIE TING GRANULES
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Smectite powder
Number of subjects: 1489
Study: 21314678

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study: 18430310

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16949492

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus trimetazidine (20 mg three times daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 55
Study: 12882414

Group type: EXPERIMENTAL
Intervention: Rock music video with suicidal content
Number of subjects: 237

Group type: COMPARATOR
Intervention: Rock music video without suicidal content
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Rock music with suicidal content
Number of subjects: 237

Group type: COMPARATOR
Intervention: Rock music with neutral content
Number of subjects: 237
Study: 10671804

Group type: EXPERIMENTAL
Intervention: Falls risk factor assessment/modification and seated balance exercise training (n = 77)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reminiscence therapy (n = 56)
Number of subjects: 133
Study: 9054841

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 18682

Group type: EXPERIMENTAL
Intervention: Borderline isolated systolic hypertension
Number of subjects: 18682
Study: 8472698

Group type: EXPERIMENTAL
Intervention: Light exercise (25W)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Transition from rest to exercise
Number of subjects: 5
Study: 3747800

Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.18 ppm O3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.24 ppm O3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 10
Study: 31414245

Group type: EXPERIMENTAL
Intervention: CaringGuidance™ plus usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study: 30381128

Group type: EXPERIMENTAL
Intervention: Leukodeplated RBC transfusion (Group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suspended RBC transfusion (Group II)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group I (Leukodeplated RBC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group II (Suspended RBC)
Number of subjects: 48
Study: 27499378

Group type: EXPERIMENTAL
Intervention: suPAR levels (measured in log2 ng/mL)
Number of subjects: 1503
Study: 24606877

Group type: EXPERIMENTAL
Intervention: Longer questionnaire asking for multiple nominations of opinion leaders
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shorter questionnaire asking for a list of named 'champions'
Number of subjects: 100
Study: 22704411

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Feitai Capsule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 60
Study: 20182833

Group type: EXPERIMENTAL
Intervention: Environmentally tailored intervention
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Basic tailored intervention
Number of subjects: 1971

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 1971
Study: 18380954

Group type: EXPERIMENTAL
Intervention: Red clover isoflavones
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 15772459

Group type: EXPERIMENTAL
Intervention: Homeopathic complex remedy Euphorbium compositum nasal drops SN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xylometazoline
Number of subjects: 0
Study: 12610033

Group type: EXPERIMENTAL
Intervention: Web-based decision support tool (DMA)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Control group (no access to DMA)
Number of subjects: 598
Study: 10353674

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE) graft
Number of subjects: 108

Group type: COMPARATOR
Intervention: Gelatin-sealed knitted Dacron graft
Number of subjects: 108
Study: 7536999

Group type: EXPERIMENTAL
Intervention: iloprost intravenously for 6 hours per day (mean dose: 1.7 ng/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no trial therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: iloprost treatment
Number of subjects: 30
Study: 2197297

Group type: EXPERIMENTAL
Intervention: Muscle stretching relaxation procedures (SR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tense-release techniques (TR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 8
Study: 7003797

Group type: EXPERIMENTAL
Intervention: 0.05% clemastine
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 10
Study: 31112954

Group type: EXPERIMENTAL
Intervention: Desidustat 100 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Desidustat 150 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Desidustat 200 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 28851409

Group type: EXPERIMENTAL
Intervention: ECG device (Kardia Mobile) recording twice daily for 1 year
Number of subjects: 200

Group type: COMPARATOR
Intervention: 7-day Holter monitor
Number of subjects: 200
Study: 26374305

Group type: EXPERIMENTAL
Intervention: Reablement
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 750
Study: 23876095

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on TMJ region
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on masseter and temporal muscles
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on both TMJ region and muscles
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 85
Study: 21799131

Group type: EXPERIMENTAL
Intervention: Warm humid air (25°C, 94% relative humidity)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cold dry air (4°C, 37% relative humidity)
Number of subjects: 21
Study: 19730208

Group type: EXPERIMENTAL
Intervention: L2 block
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control block
Number of subjects: 37
Study: 17573961

Group type: EXPERIMENTAL
Intervention: PICO templates (Protocol A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PICO templates (Protocol B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard PubMed Web interface (Protocol C)
Number of subjects: 31
Study: 15046642

Group type: EXPERIMENTAL
Intervention: Oral lactobacillus powder
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Vaginal lactobacillus pessaries
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (vaginal)
Number of subjects: 496
Study: 15273192

Group type: EXPERIMENTAL
Intervention: Cramp group (n = 21)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 72
Study: 10396713

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine (group BIB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5 mg of oxycodone in 10 ml of saline (group OIB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5 mg of oxycodone intramuscularly (group OIM)
Number of subjects: 42
Study: 7747715

Group type: EXPERIMENTAL
Intervention: Adoptive chemoimmunotherapy (Adriamycin, interleukin-2, lymphokine-activated killer cells)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chemotherapy (Adriamycin alone)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adoptive chemoimmunotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 24
Study: 2174950

Group type: EXPERIMENTAL
Intervention: Isometric handgrip test
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Psychological stressors (arithmetic, Stroop word‐color, mirror draw)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Physical stressors (isometric handgrip, cold pressor)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Gender influence
Number of subjects: 117
Study: 6769256

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Number of subjects: 0
Study: 29775437

Group type: EXPERIMENTAL
Intervention: Ceramill Motion 2 (CM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zirkonzahn (ZZ)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cad4dent (CD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weiland (WI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerec (CS)
Number of subjects: 60
Study: 29049211

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 24 hours preoperative administration (EPEA)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 1 hour preoperative administration (PEA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Celecoxib 400 mg 4 hours postoperative administration (POA)
Number of subjects: 206
Study: 27056950

Group type: EXPERIMENTAL
Intervention: Pritelivir treatment (dosage not specified) for 28 days
Number of subjects: 87
Study: 24612081

Group type: EXPERIMENTAL
Intervention: High-onion group (raw red onions: 2 × 40-50 g/day if overweight and 2 × 50-60 g/day if obese)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-onion group (raw red onions: 2 × 10-15 g/day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-onion group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-onion group
Number of subjects: 54
Study: 21961887

Group type: EXPERIMENTAL
Intervention: New Paracetamol pediatric suspension (PPS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Children's panadol (CP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Panodil baby & infant (PBI)
Number of subjects: 28
Study: 19258948

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Observation after surgical treatment
Number of subjects: 448
Study: 17239142

Group type: EXPERIMENTAL
Intervention: Magnetic navigation using a magnet‐tipped 0.014'' guidewire (Cronus guidewire) with a standard CS delivery sheath
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Magnetic navigation using a magnet‐tipped 0.014'' guidewire (Cronus guidewire) with a 'bare‐wire' approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetic navigation
Number of subjects: 50
Study: 15676171

Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg once-a-day
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg twice-a-day
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study: 12092995

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral‐B Ultra Plaque Remover
Number of subjects: 38
Study: 9830318

Group type: EXPERIMENTAL
Intervention: LARR1 group (induction with 4 days of etoposide and 4 days of high-dose ara-C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LARR2 group (induction with 4 days of etoposide plus 3 days of mitoxantrone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 24
Study: 7655964

Group type: EXPERIMENTAL
Intervention: Pulse spray thrombolysis with 0.33 mg/ml rt‐PA injected as a bolus of 0.2 ml
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional thrombolysis with 0.05 mg/ml rt‐PA infused at a rate of 10 ml/h
Number of subjects: 18
Study: 30931594

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 9
Study: 31030568

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day (control group)
Number of subjects: 80
Study: 28406125

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg OD for 24 weeks
Number of subjects: 153
Study: 26707029

Group type: EXPERIMENTAL
Intervention: Abnormal bilirubin levels
Number of subjects: 4228

Group type: EXPERIMENTAL
Intervention: Total bilirubin increase (per 1 mg/dL)
Number of subjects: 4228

Group type: COMPARATOR
Intervention: Normal bilirubin levels
Number of subjects: 4228

Group type: EXPERIMENTAL
Intervention: AST and ALT levels
Number of subjects: 4228
Study: 25107530

Group type: EXPERIMENTAL
Intervention: Accelerated HBV vaccination schedule (0, 1, and 2 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HBV vaccination schedule (0, 1, and 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor self-rated health score
Number of subjects: 0
Study: 22207416

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 542
Study: 19821962

Group type: EXPERIMENTAL
Intervention: Supplemental fluid (prescribed plus 10 mL/kg) for 5 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fluid volume prescribed
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Supplemental fluid
Number of subjects: 64
Study: 16777828

Group type: COMPARATOR
Intervention: Standard care (group 1)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Standard care plus assistance with scheduling follow-up (group 2)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Standard care plus assistance with scheduling follow-up and enrollment in a case management program (group 3)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: All groups (including standard care)
Number of subjects: 352
Study: 14993586

Group type: EXPERIMENTAL
Intervention: Fiber (glucomannan) 100 mg/kg body weight daily (max 5 g/day) for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11282766

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 30
Study: 9227205

Group type: EXPERIMENTAL
Intervention: hEGF ophthalmic solution (30 micrograms/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hEGF ophthalmic solution (100 micrograms/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8260241

Group type: EXPERIMENTAL
Intervention: Tamoxifen with 3M chemotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: 3M chemotherapy alone
Number of subjects: 94
Study: 3631731

Group type: EXPERIMENTAL
Intervention: Greater level of effort while breathing room air (25.0 ± 0.4 degrees C, 15.7 ± 0.2 mg H2O/L)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lesser level of effort while breathing cold (0.0 ± 0.5 degrees C) and dry air (0 mg H2O/L)
Number of subjects: 8
Study: 28980297

Group type: EXPERIMENTAL
Intervention: Remote preconditioning (three cycles of 5 min inflation and 5 min deflation of a blood pressure cuff on the right arm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 120
Study: 27497511

Group type: EXPERIMENTAL
Intervention: ProRoot MTA (DENTSPLY Tulsa Dental Specialties)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Biodentine (Septodont)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Negative control (dry sterile cotton pellet)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Positive control (blood‐moistened cotton pellet)
Number of subjects: 28
Study: 24834924

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 23921215

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study: 20080017

Group type: COMPARATOR
Intervention: Ondansetron 4 mg or 8 mg in adults; 0.15 mg/kg in children
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in adults
Number of subjects: 457
Study: 19214743

Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid 4 mg every 6 months
Number of subjects: 558

Group type: COMPARATOR
Intervention: Delayed zoledronic acid 4 mg every 6 months (only given if post-baseline BMD T score < -2.0 or fracture)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid
Number of subjects: 558

Group type: COMPARATOR
Intervention: Delayed zoledronic acid
Number of subjects: 558
Study: 15918823

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxford position
Number of subjects: 100
Study: 12586255

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg plus lovastatin (10, 20, or 40 mg)
Number of subjects: 548

Group type: COMPARATOR
Intervention: lovastatin (10, 20, or 40 mg)
Number of subjects: 548

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study: 10589275

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8998877

Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Demineralized bone graft
Number of subjects: 55
Study: 1662877

Group type: EXPERIMENTAL
Intervention: Temafloxacin 300 mg or 600 mg b.i.d.
Number of subjects: 584

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg or 750 mg b.i.d.
Number of subjects: 584
Study: 6789358

Group type: EXPERIMENTAL
Intervention: Reserpine at doses of 0.75‐1.5 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alpha‐methyldopa at doses of 750‐1,500 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31301123

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation over the left M1 for 10 minutes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation over the left M1 for 20 minutes
Number of subjects: 32
Study: 30430971

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study: 27184690

Group type: EXPERIMENTAL
Intervention: Adjuvant subcutaneous liraglutide 1.2 mg and insulin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 15
Study: 24738981

Group type: EXPERIMENTAL
Intervention: budesonide + formoterol
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: budesonide + montelukast
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: budesonide + doxofylline
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: budesonide + tiotropium
Number of subjects: 297
Study: 22344322

Group type: EXPERIMENTAL
Intervention: Multivalent polyclonal antibody preparation (PAP) at 10 mL·d(‐1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Monensin (MON) at 300 mg·d(‐1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multivalent polyclonal antibody preparation (PAP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Monensin (MON)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Crossbred yearling bulls (TC and CC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nellore yearling bulls (NE)
Number of subjects: 96
Study: 20956904

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 75 micrograms
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 150 micrograms
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 90
Study: 17701671

Group type: EXPERIMENTAL
Intervention: 0.5 mg of intramuscular ergometrine
Number of subjects: 510

Group type: COMPARATOR
Intervention: 10 IU of intravenous oxytocin
Number of subjects: 510
Study: 15651178

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study: 11678838

Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) programme
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 185
Study: 9131944

Group type: EXPERIMENTAL
Intervention: SeBA-GEN
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ABBOTTBASE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of SeBA-GEN and ABBOTTBASE
Number of subjects: 100
Study: 21207910

Group type: EXPERIMENTAL
Intervention: Anchored Instruction (AI)
Number of subjects: 81
Study: 2975148

Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standardised general anaesthetic technique alone
Number of subjects: 60
Study: 29538258

Group type: EXPERIMENTAL
Intervention: ADXS11-001
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ADXS11-001 + cisplatin
Number of subjects: 109
Study: 27681753

Group type: EXPERIMENTAL
Intervention: ipilimumab + RT
Number of subjects: 22
Study: 24534638

Group type: EXPERIMENTAL
Intervention: rEVAR (endovascular repair) before the trial
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: rEVAR (endovascular repair) during the trial
Number of subjects: 169

Group type: COMPARATOR
Intervention: Overall mortality before and during the trial
Number of subjects: 169

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Patients treated during the trial
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Randomised patients
Number of subjects: 169